Cutting-edge technologies to accelerate, validate, and democratize preclinical oncology.
Every Tumor, Every Stage
Using our proprietary, tunable, and tissue-specific bioinks we are developing a library of 3D tumor models that replicate key aspects associated with cancer growth and metastasis.
3D Bioprinted Tumoroids
Unveiling the Barriers: Challenges in Preclinical Oncology
Current methods of preclinical testing tail to capture the chemical and physical factors that influence cancer growth and treatment. Despite each late-stage clinical trial costing billions of dollars per drug, animal models continue to be widespread because there simply is no alternative. That is, until now.
Poor Translation
Only 3% of cancer therapeutics that start phase I clinical trials will actually make it to market1. This leads to billions of dollar wasted on clinical trials2
Diversity Gap
The medical field has historically failed to account for patient diversity corresponding to sex, race, age, and co-morbid factors
Animal Welfare
Animal testing presents an ethical dilemma, and animal model data does not necessarily translate into humans
Preclinical Oncology: Validated, Accelerated, Democratized
Validated: Clinical Results Replicated
To demonstrate the promise of our platform we will validate our tumor models against previous clinical results using a retroactive, blinded study where we will show our ability to replicate clinical data within our system - stepping away from guesswork and towards reproducible successes.
Accelerated: The Tumor Microenvironment
The microenvironment is what surrounds and supports our cells, and helps provide structure to the various tissues that make up our bodies. The physical and chemical aspects and components of a tumor's microenvironment are critical for directing how the tumor grows and spreads in the body. By replicating the tumor microenvironment, TissueTinker provides a more realistic representation of tumors as they appear in the body.
Democratized: Preclinical Testing For All
Our models are agnostic of the original cell source, and can be readily used with both patient cells and immortalized cell lines. This allows us to further democratize healthcare by testing new therapeutics on cells from patients of a variety of different backgrounds and health states.
Steps to Success
High-Throughput Analysis
Our platform supports tumors that fit within a 96-well plate, enabling rapid and reproducible high-throughput analysis. We are developing curated sample panels for nanoparticles, mAbs, and small molecule drugs.
Library Expansion
By engineering tissue-specific bioinks, we will expand our library by creating even more specialized tumor models: Every tumor, every stage.
Rare Cancers
Using our model library, we will develop new therapeutics for rare and underserved cancers by leveraging our backgrounds in mRNA technology, nanotechnology, and biotherapeutic formulation.